The epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy.
1 x 1 Baselga, J and Arteaga, CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445–2459 Crossref | PubMed | Scopus (599) | Google Scholar See all References Erlotinib is an orally active and selective tyrosine kinase inhibitor of the EGFR (EGFR-TKI) that has demonstrated antitumor activity in patients with non-small cell lung cancer (NSCLC).
2 x 2 Shepherd, FA, Rodrigues Pereira, J, Ciuleanu, T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123–132 Crossref | PubMed | Scopus (4501) | Google Scholar See all References